美股A股
StockGist
Back
8-K2026-02-12· grok-4-1-fast-non-reasoning

RZLT · Rezolute, Inc.

0001104659-26-014287

SEC filing

Summary

Rezolute, Inc. reported Q2 fiscal 2026 financial results with net loss of $22.8 million and cash position of $132.9 million as of December 31, 2025. The Phase 3 sunRIZE study for ersodetug in congenital HI missed primary and key secondary endpoints, though all participants continued into open-label extension; upLIFT tumor HI study enrollment is ongoing with topline results expected H2 2026.

Key takeaways